About NEUVIOR
NEUVIOR is a UK pharmaceutical group building infrastructure across medicines intelligence, supply, applied research and pharmacy operations.
Assurance & external validation
Why NEUVIOR exists
NEUVIOR was created to restore confidence in medicine by building better pharmaceutical infrastructure: clearer decisions, stronger governance, more resilient supply and more disciplined execution.
Incorporated in Glasgow on 4 August 2025, NEUVIOR Pharmaceuticals Ltd sits at the intersection of pharmaceutical preparation, wholesale, biotechnology R&D and software-enabled operating systems. PHARMORIS® is the flagship wedge: a medicines value operating system for health systems. Around that sits a broader group strategy spanning Rx, labs, pharmacy and future manufacturing adjacencies.
Founded 2025
Glasgow, Scotland
Pharmaceutical infrastructure
AI, supply, research and pharmacy
PHARMORIS®
Medicines value operating system
Group model
Rx, labs, pharmacy and intelligence
From intelligence to deployment
Research
Use applied product design, IP development and translational problem selection to focus on real system failures in medicines.
Infrastructure
Build platforms such as PHARMORIS® and adjacent capabilities across data, governance, supply and operational execution.
Deployment
Translate product architecture into use cases for commissioners, providers, pharmacy operators and long-term industrial partners.
What makes the company different
“NEUVIOR is designed as pharmaceutical infrastructure, not a single-product startup: evidence-led, regulated in mindset and built to compound across software, supply and care delivery.”
Infrastructure thinking
We build for the full medicines system, connecting data, supply, governance and frontline execution rather than treating them as separate silos.
Precision over hype
We use precise language about what is live, what is validated and what remains a future adjacency. That matters to NHS buyers, regulators, investors and journalists alike.
Long-term category building
PHARMORIS is the current wedge, but the wider group model creates optionality across Rx, pharmacy, research and future manufacturing capability.
Key milestones so far
A short but highly structured build period, moving from incorporation to public validation with a more disciplined pharmaceutical narrative.
NEUVIOR® incorporated
Company founded in Glasgow as a pharmaceutical group spanning manufacture, wholesale and R&D activities.
Innovate UK Growth Catalyst – New Innovators Award
Awarded for PHARMORIS™ - Generics Optimisation Platform for NHS and Global Health, 39 days from incorporation.
NHS DSPT Standards Met
Published for the 2025-26 cycle, strengthening NEUVIOR’s early NHS-facing governance posture.
PHARMORIS® trade mark published
UK00004301201 published by the IPO UK across software, AI and pharmaceutical research classes.
ZYLON™ feasibility programme
Innovate UK-backed work exploring solvent recovery and bio-intelligent materials for lower-waste pharmaceutical production.
News and insights
Why medicines infrastructure matters now
A NEUVIOR perspective on medicines value, resilient supply, governance and why health systems need operating systems rather than another layer of dashboards.
Read Full ArticleStay informed
Receive updates on PHARMORIS®, group milestones, governance progress, pilot activity and perspective pieces for investors, media and health-system stakeholders.
We respect your privacy. Unsubscribe at any time.